Loxinic

Loxinic may be available in the countries listed below.

Ingredient matches for Loxinic

Meloxicam

Meloxicam is reported as an ingredient of Loxinic in the following countries:

• Indonesia

International Drug Name Search

Donezepil Synthon

Donezepil Synthon may be available in the countries listed below.

Ingredient matches for Donezepil Synthon

Donepezil

Donepezil is reported as an ingredient of Donezepil Synthon in the following countries:

• Slovakia

International Drug Name Search

Unimax

Unimax may be available in the countries listed below.

Ingredient matches for Unimax

Felodipine

Felodipine is reported as an ingredient of Unimax in the following countries:

• Germany


• Switzerland

Ramipril

Ramipril is reported as an ingredient of Unimax in the following countries:

• Germany


• Switzerland

International Drug Name Search

Bendex

Bendex may be available in the countries listed below.

Ingredient matches for Bendex

Mebendazole

Mebendazole is reported as an ingredient of Bendex in the following countries:

• Bangladesh

International Drug Name Search

Anvomer B6

Anvomer B6 may be available in the countries listed below.

Ingredient matches for Anvomer B6

Pyridoxine

Pyridoxine is reported as an ingredient of Anvomer B6 in the following countries:

• Indonesia

International Drug Name Search

Lennon-Warfarin

Lennon-Warfarin may be available in the countries listed below.

Ingredient matches for Lennon-Warfarin

Warfarin

Warfarin sodium salt (a derivative of Warfarin) is reported as an ingredient of Lennon-Warfarin in the following countries:

• South Africa

International Drug Name Search

Furolix

Furolix may be available in the countries listed below.

Ingredient matches for Furolix

Furosemide

Furosemide is reported as an ingredient of Furolix in the following countries:

• Tunisia

International Drug Name Search

Betadine Ophthalmic

Dosage Form: ophthalmic solution
Betadine® 5%

Sterile Ophthalmic

Prep Solution

(povidone-iodine ophthalmic solution)

(0.5% available iodine)

DESCRIPTION

Povidone-Iodine is a broad-spectrum microbicide with the chemical formulas:

2-pyrrolidinone, 1- ethenyl-, homopolymer, compound with iodine; 1-vinyl-2-pyrrolidinone polymer, compound with iodine. The structural formula is as follows:

BETADINE® 5% Sterile Ophthalmic Prep Solution contains 5% povidone-iodine (0.5% available iodine) as a sterile dark brown solution stabilized by glycerin. Inactive Ingredients: citric acid, glycerin, nonoxynol-9, sodium chloride, sodium hydroxide, and dibasic sodium phosphate.

CLINICAL PHARMACOLOGY

A placebo-controlled study in 38 normal volunteers yielded data for 36 subjects who showed a mean log10 reduction of 3.05 log10 units in total aerobes at 10 minutes following prepping the skin with BETADINE® 5% Sterile Ophthalmic Prep Solution compared with reduction of 1.58 log10 units after prepping with vehicle free of the iodine complex. This placebo-controlled study indicates a mean log10 reduction by the iodine complex compared with the control solution of 1.47 log10 units at 10 minutes and 1.79 log10 units at 45 minutes. The base-line mean aerobic bacterial count was 7,586 organisms per square cm.

INDICATIONS AND USAGE

BETADINE® 5% Sterile Ophthalmic Prep Solution for the eye is indicated for prepping of the periocular region (lids, brow, and cheek) and irrigation of the ocular surface (cornea, conjunctiva, and palpebral fornices).

CONTRAINDICATIONS

Do not use on individuals known to be sensitive to iodine, or other components of this product.

WARNINGS

FOR EXTERNAL USE ONLY. NOT FOR INTRAOCULAR INJECTION OR IRRIGATION.

PRECAUTIONS:

General

No studies are available in patients with thyroid disorders; therefore, caution is advised in using BETADINE® 5% Sterile Ophthalmic Prep Solution in these patients due to the possibility of iodine absorption.

Carcinogenesis, Mutagenesis, Impairment of Fertility

No long term studies in animals have been performed to evaluate the carcinogenic or mutagenic potential of povidone-iodine. One report of the mutagenic potential of povidone-iodine indicated that it was positive in a modification of the Ames S. typhimurium model, but these results could not be reproduced by another researcher. Another test using mouse lymphoma and Balb/3T3 cells showed that povidone-iodine has no significant mutagenic or transformation capabilities. Other data indicated that it does not produce mutagenic effects in mice or hamsters according to the dominant lethal test, micronucleus test, and chromosome analysis.

Pregnancy

Category C: Animal reproduction studies have not been conducted with BETADINE® 5% Sterile Ophthalmic Prep Solution. It is also not known whether BETADINE® 5% Sterile Ophthalmic Prep Solution can cause fetal harm when administered to a pregnant woman or can affect reproductive capacity. BETADINE® 5% Sterile Ophthalmic Prep Solution should only be used on a pregnant woman if clearly needed.

Nursing Mothers

Because of the potential for serious adverse reactions in nursing infants from BETADINE® 5% Sterile Ophthalmic Prep Solution, a decision should be made to discontinue nursing or discontinue the drug, taking into account the importance of the drug to the mother.

Pediatric Use

Safety and effectiveness in pediatric patients have not been established.

Geriatric Use

No overall differences in safety or effectiveness have been observed between elderly and younger patients.

ADVERSE REACTIONS

Local sensitivity has been exhibited by some individuals to povidone-iodine ophthalmic solution.

DOSAGE AND ADMINISTRATION

While the inner surface and contents of the immediate container (i.e. bottle) are sterile, the outer surface of the bottle is not sterile. The use of the bottle in a sterile field should be avoided.

BETADINE® 5% Sterile Ophthalmic Prep Solution is used as

follows:

1. Make sure container is intact before use. To open, COMPLETELY TWIST OFF TAB, do not pull off. Gently squeeze entire contents of bottle into a sterile prep cup.

2. Saturate sterile cotton-tipped applicator to prep lashes and lid margins using one or more applicators per lid; repeat once.

3. Saturate sterile prep sponge or other suitable material to prep lids, brow and cheek in a circular ever-expanding fashion until the entire field is covered; repeat prep three (3) times.

4. While separating the lids, irrigate the cornea, conjunctiva and palpebral fornices with BETADINE® 5% Sterile Ophthalmic Prep Solution using a sterile bulb syringe.

5. After the BETADINE® 5% Sterile Ophthalmic Prep Solution has been left in contact for two minutes, sterile saline solution in a bulb syringe should be used to flush the residual prep solution from the cornea, conjunctiva, and the palpebral fornices.

HOW SUPPLIED

BETADINE® 5% Sterile Ophthalmic Prep Solution is packaged under sterile conditions and supplied in 1 fl.oz. (30 mL) form sealed blue HDPE bottles (NDC #0065 0411 30). Twenty-four (24) bottles are packed in each shipper.

Store at 15-25°C (59-77°F).

Rx Only

Single use only

       

Manufactured for:

Alcon Laboratories, Inc.

Fort Worth, TX 76134

        

Manufactured by:

Catalent Pharma Solutions, LLC

Woodstock, IL 60098

      

BETADINE® is a registered trademark of The Purdue Frederick Company.

       

9002984-1007

Principal Display Panel

NDC 0065 0411 30

Betadine® 5%

Sterile Ophthalmic Prep Solution

(povidone-iodine

ophthalmic solution)

For Pre-Operative Prep and

Irrigation of the Ocular and

Periocular Surfaces

Flush eye thoroughly with

sterile saline solution after

each use.

Rx Only

1 Fl. Oz. (30 mL)

Alcon®

BETADINE  povidone-iodine  solution

Product Information Product Type HUMAN PRESCRIPTION DRUG NDC Product Code (Source) 0065-0411 Route of Administration OPHTHALMIC DEA Schedule

Active Ingredient/Active Moiety Ingredient Name Basis of Strength Strength POVIDONE-IODINE (IODINE) IODINE 5 mg  in 1 mL

Inactive Ingredients Ingredient Name Strength CITRIC ACID MONOHYDRATE   GLYCERIN   NONOXYNOL-9   SODIUM CHLORIDE   SODIUM HYDROXIDE   SODIUM PHOSPHATE, DIBASIC

Product Characteristics Color      Score      Shape Size Flavor Imprint Code Contains

Packaging # NDC Package Description Multilevel Packaging 1 0065-0411-30 30 mL In 1 BOTTLE None

Marketing Information
Marketing Category	Application Number or Monograph Citation	Marketing Start Date	Marketing End Date
NDA	NDA018634	04/01/2000

Labeler - Alcon Laboratories, Inc. (008018525)

Registrant - Alcon Laboratories, Inc. (008018525)

Establishment
Name	Address	ID/FEI	Operations
Catalent Pharma Solutions, LLC		043911403	MANUFACTURE

Revised: 07/2011Alcon Laboratories, Inc.

Pulmonary Fibrosis Medications

Definition of Pulmonary Fibrosis: Idiopathic pulmonary fibrosis involves scarring or thickening of tissues deep in the lung without a known cause.

Drugs associated with Pulmonary Fibrosis

The following drugs and medications are in some way related to, or used in the treatment of Pulmonary Fibrosis. This service should be used as a supplement to, and NOT a substitute for, the expertise, skill, knowledge and judgment of healthcare practitioners.

Topics under Pulmonary Fibrosis

• Idiopathic Pulmonary Fibrosis (1 drug)

Drug List:

Remicade